Study shows statins can improve IPF patient outcomes

The study “Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis,” was recently published in the journal Thorax. The researchers in this study compiled patient outcome data from all of the previous 3 major clinical trials on pirfenidone, the two CAPACITY trials and the ASCEND trial.

The combined patient data was analyzed based on those patients who were taking statin drugs during the clinical trials and patients who were not taking statin drugs. Among all the patients, 276 (44%) patients were statin users and 348 (56%) did not use statins. Both groups had similar characteristics at baseline, but the statin users were on average older and had higher prevalence of cardiovascular disease. Continue reading

Esbriet (pirfenidone) found to reduce IPF progression in all disease stages

When pirfenidone (Esbriet) was first approved for IPF, there was some concern initially that pirfenidone may be best suited for patients with mild to moderate disease.  A new study, “Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function,” was published in the European Respiratory Journal in 2016.

The study compiled outcome data from all three of the major pirfenidone Phase-III trials. The researchers re-analyzed the pooled data by stratifying patients based on their base-line lung function at the start of these clinical trials and compared the outcomes between patients with mild and more severe IPF at the beginning of these trials. Results from the study showed that the effectiveness of pirfenidone was independent of the patient having a more preserved or less preserved lung function at baseline. The researchers concluded that “These findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population.” This gives us more confidence that pirfenidone is similarly effective in moderate to severe IPF stages and should be used in all patients with IPF. Continue reading

Introduce “My Account”

We have rolled out a new feature on our website – “My Account“. This feature was previously hidden in the check out process, where customers can create a new user account by checking the “create new account” checkbox. Recently, we have made some enhancement to “My Account” and opened it up for public. “My Account” can be accessed via the main navigation menu on the website or via direct link: https://www.liferelayhealthcare.com/my-account/ Continue reading